MAZE financial statements
The full income statement, balance sheet, and cash-flow statement for Maze Therapeutics Inc. (MAZE), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 |
|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| Revenue | — | 168M | |
| 143M+30.0% | 110M | ||
| Research & development | 108M+29.9% | 83.5M | |
| Selling, general & administrative | 34.5M+30.4% | 26.4M | |
| General & administrative | 34.5M+30.4% | 26.4M | |
| Operating income | -143M-348.1% | 57.6M | |
| Gain (loss) on equity securities | 110K | — | |
| Pre-tax income | -131M-345.5% | 53.4M | |
| Income tax | 0.00-100.0% | 1.17M | |
| -131M-351.0% | 52.2M | ||
| Net income to common | -131M-3950.8% | 3.40M | |
| -$3.05-344.0% | $1.25 | ||
| EPS (basic) | -$3.05-314.8% | $1.42 | |
| Weighted-avg shares (basic) | 43.0M+1693.6% | 2.40M | |
| Weighted-avg shares (diluted) | 43.0M+1474.0% | 2.73M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| 350M+73.4% | 202M | ||
| Cash & equivalents | 189M-3.8% | 197M | |
| Short-term investments | 153M | — | |
| Prepaid expenses | 7.80M+60.5% | 4.86M | |
| 397M+65.1% | 241M | ||
| Property, plant & equipment | 5.04M-24.4% | 6.67M | |
| Operating lease right-of-use | 20.1M-13.5% | 23.3M | |
| Long-term investments | 18.1M | — | |
| Other non-current assets | 3.05M-61.2% | 7.87M | |
| 22.6M+9.1% | 20.7M | ||
| Accounts payable | 1.79M-7.5% | 1.94M | |
| Current lease liability | 4.79M+3.5% | 4.63M | |
| 42.2M-3.4% | 43.6M | ||
| Non-current lease liability | 18.5M-15.8% | 22.0M | |
| Operating lease liability (total) | 23.3M | — | |
| Other non-current liabilities | 1.09M+12.9% | 969K | |
| 355M+214.1% | -311M | ||
| Preferred stock | 0.00 | 0.00 | |
| Common stock | 49.0K+2350.0% | 2.00K | |
| Additional paid-in capital | 844M+1687.3% | 47.2M | |
| Retained earnings | -490M-36.6% | -358M | |
| Total equity incl. non-controlling | 355M+214.1% | -311M | |
| Total liabilities & equity | 397M+65.1% | 241M | |
| Common shares issued | 49.3M+1916.3% | 2.45M | |
| Common shares outstanding | 49.3M+1916.3% | 2.45M | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| -112M-247.4% | 76.0M | ||
| Depreciation & amortization | 2.40M-27.1% | 3.30M | |
| Share-based compensation | 16.4M+70.0% | 9.65M | |
| Change in payables | -27.0K+86.8% | -204K | |
| Other operating activities | 21.0K-96.4% | 577K | |
| -171M-14805.1% | -1.15M | ||
| Capital expenditure | 794K-30.8% | 1.15M | |
| Free cash flow | -113M-250.7% | 74.8M | |
| Acquisitions | 0.00 | 0.00 | |
| 275M+196.5% | 92.8M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Income taxes paid | — | 1.23M | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| Market cap | 2.04B | — | |
| P/S | 12.2× | — | |
| P/B | 5.8× | — | |
| Source filing | 10-K | 10-K |
About this data
Source: MAZE’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all MAZE filings on SEC EDGAR → Not investment advice.